MILLIPLEX^® Human Neurodegenerative Disease Panel

MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany

Luminex is a registered trademark of Luminex Corp

xMAP is a registered trademark of Luminex Corp

MILLIPLEX^® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 5 analytes in human cerebrospinal fluid (CSF).Analytes included: S100B, Amyloid β40 (Aβ40), Amyloid β42 (Aβ42), sRAGE, GDNF.Note: Serum and plasma are not verified sample types for this assay.Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.

For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.

Comprehensive Alzheimer′s Pathway Coverage: Simultaneously quantify amyloid-beta peptides, S100B neuroinflammation marker, sRAGE receptor, and GDNF neuroprotective factor, providing complete insight into key Alzheimer′s disease mechanisms in one assay.
CSF-Optimized Excellence: Specifically verified for cerebrospinal fluid analysis with exceptional spike recovery (84-108%), ensuring accurate quantification of these critical brain-derived biomarkers in precious CSF samples.
Streamlined Neuroscience Discovery: Eliminate the complexity of five separate assays with our integrated multiplex format, accelerating your Alzheimer′s research while maximizing the utility of limited CSF samples for comprehensive biomarker profiling.
Target Discovery Power: Leverage biomarkers spanning amyloid aggregation, neuroinflammation, and neuroprotection pathways to identify therapeutic interventions targets.
Precision-Engineered Reliability: Trust in < 10% intra-assay precision across all analytes and < 15% inter-assay variability, delivering the data consistency essential for breakthrough neurodegenerative research.

Alzheimer′s pathology is shaped by a dynamic interplay between toxic aggregates and protective responses. Amyloid-beta peptides 40 and 42 form the core of senile plaques. S100B, a calcium-binding protein, interacts with these aggregates and activates RAGE signaling, amplifying neuroinflammation. sRAGE, in contrast, acts as a decoy receptor, potentially limiting amyloid transport across the blood-brain barrier. GDNF supports neuronal survival, offering a counterbalance to degenerative forces.